News
GHSI
--
0.00%
--
Guardion Health Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements, and medical de...
GlobeNewswire · 09/09 12:30
BRIEF-Guardion Health Sciences Announces Quarterly Loss Per Share Of $0.19
reuters.com · 08/16 12:27
Guardion Health Sciences Q2 EPS $(0.19) Down From $(0.05) YoY, Sales $1.22M Up From $1.19M YoY
Guardion Health Sciences (NASDAQ:GHSI) reported quarterly losses of $(0.19) per share. This is a 280 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $1.22 million
Benzinga · 08/16 12:16
-- Earnings Flash (GHSI) GUARDION HEALTH SCIENCES Reports Q2 Revenue $1.2M
MT Newswires · 08/16 08:30
Guardion Health Sciences to Exhibit at the American Society of Cataract and Refractive Surgery Annual Meeting
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutrition, supplements, medical foods and medical devi...
GlobeNewswire · 07/22 20:15
Acquiring Activ Nutritional Is Perfect for Growth, Says Guardion Health Sciences
Guardion Health Sciences Inc. (NASDAQ: GHSI) is confident that its recent acquisition of Activ Nutritional LLC will be a strong catalyst for growth.
Benzinga · 06/25 19:20
BRIEF-Guardion Health Sciences To Be Added To The Russell 3000 Index
reuters.com · 06/14 13:20
Guardion Health Sciences names Craig Sheehan as chief commercial officer
Guardion Health Sciences (GHSI) announces the appointment of Craig Sheehan as the company's chief commercial officer.Sheehan joins Guardion following the company’s recent acquisition of Activ Nutritional. He was the senior executive responsible for the Via...
Seekingalpha · 06/03 12:30
Guardion Health closes Activ Nutritional acquisition
Guardion Health Sciences (GHSI) has closed the previously announced acquisition of Activ Nutritional for $26M.Activ Nutritional will provide a "significant boost" to Guardion's current operating revenues and "contribute substantially" to the
Seekingalpha · 06/02 13:18
BRIEF-Guardion Health Sciences Says CFO Andrew Schmidt To Step Down
reuters.com · 05/24 21:59
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers Advaxis, Inc. (NASDAQ: ADXS) shares rose 29.6% to $0.6289 in pre-market trading after jumping over 14% on Tuesday.
Benzinga · 05/19 11:07
Guardion Health to acquire Activ Nutritional for $26M
Guardion Health Sciences ([[GHSI]] +10.8%) has entered into an equity purchase agreement with Adare Pharmaceuticals to acquire all of the equity of Activ Nutritional for $26M.Adare owns the Viactiv line
Seekingalpha · 05/18 13:33
BRIEF-Guardion Health Sciences To Acquire Activ Nutritional And Its Viactiv Brand Of Products
reuters.com · 05/18 13:28
Guardion Health Sciences To Acquire Activ Nutritional From Adare Pharmaceuticals For Cash Payment Of $26M
Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements and
Benzinga · 05/18 13:26
Guardian Health to Acquire Maker of Viactiv Nutrition Supplements for $26 Million; Shares Rise
MT Newswires · 05/18 10:04
BRIEF-Guardion Health Sciences Reports Qtrly Loss Per Share Of $0.13
reuters.com · 05/17 21:06
Guardion Health Sciences reports Q1 results
Guardion Health Sciences (GHSI): Q1 GAAP EPS of -$0.13.Revenue of $0.23M (-4.2% Y/Y)Shares +0.64%.Press Release
Seekingalpha · 05/17 20:42
-- Earnings Flash (GHSI) GUARDION HEALTH SCIENCES Reports Q1 Loss $-0.13
MT Newswires · 05/17 16:26
BRIEF-Guardion Health Sciences Initiates Placebo-Controlled Clinical Trial Involving Proprietary GlaucoCetin Product
reuters.com · 05/03 13:23
Guardion Health initiates GlaucoCetin glaucoma trial
Guardion Health Sciences (GHSI) announces the initiation of a placebo-controlled clinical trial to study the impact on visual function, as measured by visual field sensitivity, in patients with glaucoma after
Seekingalpha · 05/03 12:16
Webull provides a variety of real-time GHSI stock news. You can receive the latest news about Guardion Health Sciences through multiple platforms. This information may help you make smarter investment decisions.
About GHSI
Guardion Health Sciences, Inc. is a specialty health sciences company that has developed medical foods and medical devices in the ocular health space. The Company is focused on developing nutraceuticals that seeks to provide supportive health benefits to consumers. The Company operates through two segments: Medical Foods and Nutraceuticals, and Medical Devices. The Medical Foods and Nutraceuticals segment provides a portfolio of science-based, clinically supported nutrition, medical foods and supplements. The Medical Devices segment includes a portfolio of medical diagnostic devices, which are focused on the ocular space and contrast testing. The Company’s medical devices and accessories are used to measure visual function and certain anatomical features of the eye that detect early disease and monitor changes over time. The Company's products include Lumega-Z, GlaucoCetin, MapcatSF and others.